Efficacy and Acceptability of Lanreotide Autogel^® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR

Abstract

Lan-ATG 120 mg injected at intervals of 56, 42 and 28 days provided equivalent hormonal control and QoL to Oct-LAR 10, 20 and 30 mg injected every 28 days, respectively. The proportion of patients preferring Lan-ATG treatment was greater in the longer injection interval groups.

Expert consensus document: A consensus on the medical treatment of acromegaly

“…6,18,24 Long-term (>3 years) results on the efficacy and safety profile of SRLs are reassuring (HQ), 18,25,26 and lowering the SRL dose or decreasing the frequency of administration of SRLs might be considered for patients with long-term control of acromegaly (VLQ). 27 When reducing the SRL dose or decreasing the frequency of administration, patients should be reassessed at regular intervals to ensure maintenance of therapeutic effect (SR).…”

Akromegalia — nowe spojrzenie na pacjenta. Polskie propozycje postępowania diagnostyczno-terapeutycznego w akromegalii w świetle aktualnych doniesień

“…Currently, there are two long-acting somatostatin analogues used in Poland. Lanreotide autogel is available in 60, 90 and 120 mg ampoules, for subcutaneous administration every 28 days, with a possible extension of the interval between injections to 56 days for the dose of 120 mg [9,19]. Octreotide LAR is manufactured in 10, 20 and 30 mg ampoules, for intramuscular administration every 28 days, with a possible dose increase to 40 mg every four weeks in patients for whom a 30 mg dose is inefficient [20].…”

“…The current possibility of using lanreotide autogel 120 mg less than once a month (even every 56 days) significantly may reduce treatment costs and increase the patient's comfort and quality of life [9,19,22].…”

Dawkowanie i koszt lanreotydu Autogel 120 mg stosowanego w leczeniu akromegalii w Polsce — wyniki 2-letniego badania Lanro-Study

“…The possibility of extending dosing intervals of drugs administered in injections may positively influence patients' preference to treatment, compliance, and quality of life [1]. Studies have been conducted to investigate the efficacy and acceptability of extending the dosing interval beyond monthly [3,4]. One study, conducted in Germany, enrolled patients who were previously treated with octreotide LAR doses of 10 mg, 20 mg, and 30 mg monthly and then switched to lanreotide AUTOGEL 120 mg (ATG120) at intervals of every 56, 42, and 28 days, respectively [3], and the other was an international study enrolling patients well controlled on octreotide 10 or 20 mg (LEAD study) [4].…”

“…Studies have been conducted to investigate the efficacy and acceptability of extending the dosing interval beyond monthly [3,4]. One study, conducted in Germany, enrolled patients who were previously treated with octreotide LAR doses of 10 mg, 20 mg, and 30 mg monthly and then switched to lanreotide AUTOGEL 120 mg (ATG120) at intervals of every 56, 42, and 28 days, respectively [3], and the other was an international study enrolling patients well controlled on octreotide 10 or 20 mg (LEAD study) [4]. The results demonstrated for both studies that extended dosing is effective at achieving biochemical control with at least similar rates of control in patients who responded to the somatostatin analogues.…”